Impact of comparative effectiveness research on Medicare coverage of direct oral anticoagulants - Supplementary appendices.

<strong>Appendix 1</strong>: Summary of the key characteristics of the included studies (n=39) Appendix 2: Change points identified for the five outcome variables using Binary Segmentation change point analysis for dabigatran, rivaroxaban and apixaban. Appendix 3: CPA plot displaying the percentage of the Medicare plans covering each DOAC with quantity limit from 2011-2017. Appendix 4: CPA plot displaying the percentage of the Medicare plans covering each DOAC under prior authorization from 2011-2017. <strong>Appendix 5</strong>: CPA plots displaying the percentage of the Medicare plans covering each DOAC with type of cost sharing at preferred pharmacies (0= not offered, 1= copay, 2= coinsurance) from 2011-2017. Appendix 6<strong>: </strong>CPA plot displaying the mean percentages of coinsurance (i.e. type of cost sharing) at preferred pharmacies for each DOAC from 2011-2017. <br>